Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions
thereof
    1.
    发明授权
    Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof 失效
    吡啶并[2,3-D]嘧啶衍生物及其药物组合物

    公开(公告)号:US6136810A

    公开(公告)日:2000-10-24

    申请号:US66370

    申请日:1998-04-30

    IPC分类号: C07D471/04 A61K31/505

    CPC分类号: C07D471/04

    摘要: This invention relates to compounds (I) or pharmaceutically acceptable salts thereof, having a function to inhibit type IV phosphodiesterase (PDE) ##STR1## [X: an oxygen atom or a sulfur atom, R.sup.1 : a lower alkyl group, a cycloalkyl-lower alkyl group or a cycloalkyl group,R.sup.2 : a hydrogen atom, a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, a hydroxy-lower alkyl group, a mercapto-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkylthio-lower alkyl group, a lower alkanoyloxy-lower alkyl group, a lower alkanoylthio-lower alkyl group, a lower alkanoyl-lower alkyl group, a hydroxyimino-lower alkyl group, a lower alkoxyimino-lower alkyl group, a cycloalkyl group, an aryl group or a lower alkanoyl group,R.sup.3 : a hydrogen atom, a halogen atom or a lower alkyl group,R.sup.4 : a hydrogen atom or a lower alkyl group,R.sup.5 : a cycloalkyl group; a naphthyl group substituted; a five- or six-membered monocyclic hetero ring group having 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom; or a group represented by the formula ##STR2## amd F.sup.6 : a halogen atom, a lower alkyl group, a halogeno-lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group].

    摘要翻译: PCT No.PCT / JP96 / 03389。 371日期:1998年4月30日 102(e)1998年4月30日PCT PCT 1996年11月20日PCT公布。 公开号WO97 / 19078 日期:1997年5月29日本发明涉及具有抑制IV型磷酸二酯酶(PDE)的功能的化合物(I)或其药学上可接受的盐[X:氧原子或硫原子,R 1:低级烷基,环烷基 - 低级烷基或环烷基,R2:氢原子,卤素原子,低级烷基,卤代低级烷基,羟基低级烷基,巯基低级烷基,低级烷氧基 - 低级烷基 低级烷酰氧基 - 低级烷基,低级烷酰硫基 - 低级烷基,低级烷酰基 - 低级烷基,低级烷酰基 - 低级烷基,羟基亚氨基 - 低级烷基,低级烷氧基亚氨基 - 低级烷基,低级烷酰氧基 - 低级烷基 环烷基,芳基或低级烷酰基,R3:氢原子,卤素原子或低级烷基,R4表示氢原子或低级烷基,R5表示环烷基。 萘基取代; 具有1-4个选自氮原子,氧原子和硫原子的杂原子的五元或六元单环杂环基; 或由式amd F6表示的基团:卤素原子,低级烷基,卤代低级烷基,羟基,低级烷氧基,氰基或硝基]。

    Morpholine derivatives
    2.
    发明申请
    Morpholine derivatives 失效
    吗啉衍生物

    公开(公告)号:US20060241302A1

    公开(公告)日:2006-10-26

    申请号:US10561838

    申请日:2004-06-29

    摘要: Provided is a compound capable of inhibiting production or secretion of β amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.

    摘要翻译: 提供能够抑制β淀粉样蛋白的产生或分泌的化合物。 由下式(1)表示的化合物:其中R 1表示可以具有取代基的杂环基,R 2表示可以具有 可以具有取代基的取代基或杂环基,R 3表示可以具有取代基的环状烃基或可以具有取代基的杂环基,R 4, 表示氢原子或C 1-6烷基,X表示-S - , - SO-或-SO 2 - )。 其N-氧化物或S-氧化物; 其盐; 或其溶剂合物; 和含有它们中任何一种的药物。

    5-hydroxypyrimidine-4-carboxamide derivative
    3.
    发明授权
    5-hydroxypyrimidine-4-carboxamide derivative 有权
    5-羟基嘧啶-4-甲酰胺衍生物

    公开(公告)号:US08785462B2

    公开(公告)日:2014-07-22

    申请号:US13503340

    申请日:2010-10-20

    CPC分类号: C07D401/06 C07D401/14

    摘要: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.

    摘要翻译: 本发明提供了促进促红细胞生成素生成的化合物。 本发明提供由式(1)表示的化合物:[其中,R1:式(1A):[其中,R4和R5:H,卤素或烷基; R6:H,卤素,烷基等; R7:可取代的羟烷基,可取代的羟基卤代烷基,可取代的烷氧基烷基等; 取代基组α:氧代,羟基,氨基等; 环Q1:单环杂环基; 环Q2:单环烃环基或单环杂环基; 环Q3:单环烃环基或单环杂环基; X:单键,亚甲基,亚乙基等); R2:烷基或甲硫基; 和R 3:H或甲基]等。

    QUINOXALINE COMPOUND
    5.
    发明申请
    QUINOXALINE COMPOUND 有权
    喹啉化合物

    公开(公告)号:US20110319385A1

    公开(公告)日:2011-12-29

    申请号:US13254368

    申请日:2010-03-04

    摘要: [Problem]Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.[Means for Solution]The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

    摘要翻译: [问题]提供具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍,排尿功能障碍和膀胱/尿道疾病的药剂的活性成分的化合物等。 [解决方案]本发明人已经研究了具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍,排尿功能障碍和膀胱/尿道疾病等的活性成分的化合物 ,因此已经发现咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有抑制PDE9的作用,从而完成了本发明。 本发明的咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有PDE9抑制作用,可用作预防和/或治疗储存功能障碍,排尿功能障碍和膀胱/尿道疾病等的药剂。

    5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE
    10.
    发明申请
    5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE 有权
    5-羟基嘧啶-4-羧酰胺衍生物

    公开(公告)号:US20120220609A1

    公开(公告)日:2012-08-30

    申请号:US13503340

    申请日:2010-10-20

    CPC分类号: C07D401/06 C07D401/14

    摘要: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group α: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.

    摘要翻译: 本发明提供了促进促红细胞生成素生成的化合物。 本发明提供由式(1)表示的化合物:[其中,R1:式(1A):[其中,R4和R5:H,卤素或烷基; R6:H,卤素,烷基等; R7:可取代的羟烷基,可取代的羟基卤代烷基,可取代的烷氧基烷基等; 取代基组α:氧代,羟基,氨基等; 环Q1:单环杂环基; 环Q2:单环烃环基或单环杂环基; 环Q3:单环烃环基或单环杂环基; X:单键,亚甲基,亚乙基等); R2:烷基或甲硫基; 和R 3:H或甲基]等。